This classification is used to direct the use of targeted therapies such as endocrine-based therapy for hormone receptor positive (HR+) breast cancer and Her2-based therapy such as trastuzumab, lapatinib and pertuzumab for Her2-enriched cancers [34]–[35]. Here, NR4A1 is linked to breast carcinoma.